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Our purpose was to determine if total body irradiation
(TBI) with lung dose reduction protects against subse-
quent radiation-induced deterioration in pulmonary func-
tion. Between July 1997 and August 2004, 181 consecutive
patients with hematologic malignancies received fractio-
nated TBI before allogeneic peripheral blood stem cell
transplant. The ﬁrst 89 patients were treated to a total
dose of 13.6Gy. Thereafter, total body dose was
decreased to 12Gy with lung dose reduction to 9 or
6Gy. All patients underwent pulmonary function test
evaluation before treatment, 90 days post-treatment, then
annually. Median follow-up was 24.0 months. Eighty-nine
patients were treated with lung shielding, and 92 without.
At 1-year post transplant, there was a small but signiﬁcant
difference in lung volume measurements between patients
with lung shielding and those without. This was not
observed at the 2-year time point. When stratiﬁed by good
(4100% predicted) or poor (p100% predicted) baseline
lung function, patients with poor function demonstrated
protection at 1 year with lung shielding, while those with
good initial lung function did not. TBI with or without
lung dose reduction has a small but statistically signiﬁcant
effect on pulmonary function measured at 1 year but not
2 years post irradiation.
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Introduction
Total body irradiation (TBI) is important in the prepara-
tion of patients for bone marrow or peripheral blood stem
cell transplant (PBSCT) in the treatment of various
malignancies.1–9 Although regimens employing chemo-
therapy alone may be effective, evidence suggests that
TBI improves post transplant survival compared to the use
of chemotherapy alone.10–12 The addition of TBI has
several advantages including the absence of cross-resistance
of host marrow cells to different chemotherapeutic agents
and the ability to sterilize disease in ‘sanctuary’ sites which
are not easily penetrated by chemotherapeutic agents.13,14
Pulmonary toxicity may result from TBI as an acute or a late
complication.15–22 Studies have shown that the severity depends
on both dose rate and total dose administered.22–26 Several
strategies have emerged to address this complication, including
increasing the fractionation schedule to decrease the radiation
dose administered at any one time26–34 and reducing the lung
dose directly by utilizing lung shielding.17,28 Several studies
have described an association between lung dose reduction
and pulmonary-related mortality and overall survival.35–38
Previous analysis of this cohort demonstrated that stratiﬁca-
tion by pretreatment pulmonary function testing (PFT)
identiﬁed patients for whom lung shielding resulted in a 20%
1-year survival beneﬁt.35
In this study, we investigated whether, in addition to
improving survival, TBI with lung dose reduction protects
against radiation-induced, post treatment deterioration in
lung function as measured by standard PFTs.
Methods
Study group
Between July 1997 and August 2004, 181 consecutive
patients with hematologic malignancies received a T cell-
depleted PBSCT from an HLA-matched sibling. These
patients were enrolled in one of ﬁve National Heart, Lung
and Blood Institute’s (NHLBI) institutional review board-
approved protocols (97-H-0099, 99-H-0046, 02-H-0111,
03-H-0192, 04-H-0112). This is a report of all patients
enrolled on these protocols with adequate follow-up for
meaningful analysis.
Conditioning regimen
Three pretransplant conditioning regimens were employed
in consecutive time periods to prepare the patient for
PBSCT. Regimen A was administered from April 1997 to
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December 2001 (n¼ 89) consisted of TBI administered to a
dose of 13.6Gy with no lung shielding, resulting in a lung
dose of more than 13.6Gy to the lungs due to tissue
density, and cyclophosphamide 120mg/kg. Regimen B was
administered from February 2002 to May 2003 (n¼ 35) and
comprised TBI to a dose of 12Gy with lung shielding,
cyclophosphamide 120mg/kg and ﬂudarabine 125mg/m2.
In this regimen, lung shielding was customized for each
patient such that the total prescribed lung dose was reduced
to 9Gy. Regimen C consisted of 12Gy of TBI with lung
shielding (6Gy prescribed lung dose), cyclophosphamide
120mg/kg and ﬂudarabine 125mg/m2 from June 2003 to
August 2004 (n¼ 57). Patients who had lung shielding
received a radiation boost dose to the mediastinum to bring
the total dose to 12Gy to ensure adequate ablation of
sternal and mediastinal myeloid tissues.
Radiation technique
During regimen A, TBI was administered using lateral
ﬁelds without any lung shielding. The patient was placed
4m from the treatment machine with the collimator fully
open. After treatment of one lateral ﬁeld, the patient was
turned to allow treatment of the opposed ﬁeld. Dose was
calculated using the midpoint of the separation distance
measured from the patient’s hips in the sitting position.
Patients received 1.7Gy twice daily for 4 days. Daily
fractions were 6 h apart. Dose rate at midplane was
approximately 0.12Gy/min. A compensator was used to
minimize dose gradients produced by different tissue
thicknesses in the head-and-neck region and torso. Dose
was veriﬁed using diodes placed on the patient’s skin in the
lateral neck, axilla, hip, midthigh and midcalf.
Regimen B lowered the total prescribed dose from 13.6 to
12Gy, given in 1.5Gy twice-daily fractions. Initially, under
regimen B, the cumulative lung dose was limited to 9Gy.
The lung dose was further reduced by regimen C to 6Gy.
Lung dose was selectively reduced by the addition of a
50% partial transmission lung block for the lateral ﬁelds.
Computed tomography (CT) simulation with the patient in
the treatment position was used to localize the apex and
inferior border of the lung. Dose was veriﬁed with diodes
placed as above. With this technique, the mediastinum,
vertebral bodies and humeral heads under the partial
transmission lung block also only received 50% of the dose
from the lateral ﬁelds. Dose to these structures was
supplemented by anterior and posterior boost ﬁelds to
bring the dose to 12Gy. These boost ﬁelds were given at
1-m treatment distance with a match at the superior and
inferior ﬁeld borders of the lateral ﬁeld lung block. Five
half-value layer lung blocks minimized additional dose to
the lungs.
For both regimens B and C, the dose rate at midplane
was approximately 0.12Gy/min for the lateral ﬁelds and
2Gy/min for the anterior and posterior boost ﬁelds. Dose
volume histogram analysis veriﬁed that 50% of the lung
received approximately 50% of the total dose. Approxi-
mately 15% of both the left and right lungs received 100%
of the dose. With the previously described lateral ﬁelds-only
method (regimen A), more than 90% of the lung received at
least 100% of the prescribed dose.
Peripheral blood stem cell transplant regimen
Patients were enrolled in one of ﬁve NHLBI protocols for
PBSCT. In the ﬁrst protocol, patients received a T cell-
depleted granulocyte colony-stimulating factor-mobilized
PBSCT by using the Ceprate selection system (CellPro,
Bothell, WA, USA). Subsequent protocols used an Isolex
300 cell separator, as described previously.39 CD34 cells
were positively selected using anti-CD34 beads, and
residual T cells were removed with a cocktail of anti-
CD2, -CD6 and -CD7 antibody-coated beads. The CD34
cell dose ranged from 2.45 to 15.90 106 cells/kg recipient
weight (median, 5.0 106/kg); the T-cell dose was 0.2–
1.0 105 CD3 cells/kg. In the absence of GVHD or unless
molecular remission was documented in chronic myeloid
leukemia, T cells were added back on days 45 and 100, or
day 60. Cyclosporine (CSA) was administered to prevent
transplant rejection and dose varied according to protocol.
All patients started CSA either on day 44 (if T cells were
added back on day 45) or on day 59 (if T cells were added
back on day 60), and it was continued until at least day 130
(or longer if chronic GVHD occurred). Standard pro-
phylaxis against infection included ﬂuconazole through
day 100, cotrimoxazole for 6 months after transplantation,
and weekly surveillance for cytomegalovirus antigenemia,
as described previously.39,40 Acute GVHD was managed
with high-dose steroids. Steroid-refractory patients who
showed no improvement after 7 days of treatment received
combined treatment with antitumor necrosis factor (inﬂix-
imab) and anti-CD25 (daclizumab) monoclonal antibodies,
as described previously.
Pulmonary function testing
Baseline PFTs were obtained for all patients 5–21 days
before PBSCT. Ventilatory capacity was measured by forced
vital capacity (FVC), forced expiratory volume in the ﬁrst
second (FEV1), the FEV1/FVC ratio and peak expiratory
ﬂow. Lung volume measurements (by helium dilution)
included vital capacity (VC), total lung capacity, residual
volume and the residual volume/total lung capacity ratio.
Diffusion capacity for carbon monoxide (DLCO) was
determined by using a carbon monoxide single-breath
technique with correction for hemoglobin concentration.41
PFTs were expressed as a percentage of the predicted values
in healthy controls with corresponding age, sex and smoking
habits. Eligibility criteria for enrollment into protocols
included DLCO460% of predicted. For this analysis,
FEV1 and DLCO limits of 100% of predicted were used to
identify at-risk patients with a combination of abnormal
inspiratory function and gas diffusion, respectively.
Statistical analysis
In the ﬁrst analysis, the average preirradiation value for
each PFT parameter was compared to the value at 1 year
after transplantation for both the lung shielding and no-
lung shielding groups. Patients were then stratiﬁed by
preradiation baseline PFT values into good (4100%
expected) and poor (p100% expected) groups. This
analysis was also performed on the subgroup of patients
who had 2 years of follow-up.
In a second analysis, an estimate of linear change of each
PFT parameter over time (in units of change in % predicted
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per year) was estimated by ﬁtting a least-squares regression
line to each patient’s available data and examining the
slope of the resulting line. This gives an estimate of the rate
of change in pulmonary function over time and, unlike in
the previous analyses, all longitudinal follow-up measures
are used. The distribution of these estimated slopes for the
good and poor baseline PFT groups was then compared.
This analysis was performed on the group of patients for
whom 1 year or greater PFT data were available.
Results
In total, 89 patients were treated without lung shielding and
92 were treated with lung shielding. Median follow-up was
24.0 months (range 0.26–119.3 months). One hundred and
nine patients had 1 year of follow-up; 91 patients had 2
years of follow-up. Patient demographics are listed in
Table 1 and are similar between groups.
In the initial analysis, the effect of lung shielding on
changes in PFT values at 1 and 2 years (Table 2) for all
patients was assessed. Positive values indicate an improve-
ment in the pulmonary function parameter while negative
values signify a decline. There was a small, but statistically
signiﬁcant, difference between the FEV1 and VC values for
all patients at the 1-year follow-up point. There was no
difference in DLCO measurements. There was no statistically
signiﬁcant difference in the change in lung function between
those patients with lung shielding and those with no lung
shielding measured at 2 years post transplant. Furthermore,
there was no difference in PFT measurements between the
two lung shielding radiation doses (9 versus 6Gy).
When patients were stratiﬁed by good or poor lung
function as deﬁned in the methods section, those with poor
lung function demonstrated a beneﬁt from lung shielding at 1
year, while those with good preirradiation lung function had
a much smaller and statistically nonsigniﬁcant beneﬁt of lung
shielding on lung function (Table 3). This was also observed
when poor lung function was deﬁned as p80% predicted
(data not shown). We did not observe this differential lung
shielding effect when patients were stratiﬁed by good and
poor lung function at 2 years (data not shown).
The rate of change in lung function over time was
compared for all patients with at least 1 year of follow-up
using a least-squares regression as described above
(Table 4). This analysis revealed no difference in the rate
of change in lung function over time between those patients
with lung shielding and those without lung shielding. Once
again, this was the case when looking at all patients
together and when patients were stratiﬁed by good or poor
lung function.
Discussion
This study shows that TBI with lung dose reduction may
result in small improvements in long-term, post transplant
Table 1 Patient demographics
Lung
shielding
(n¼ 92)
No lung
shielding
(n¼ 89)
P-values
% Male 50 58 0.30
Age (years), median (range) 32 (10–55) 38 (10–56) 0.006
% Positive smoking history 3 11 0.05
Presenting disease (%)
AML 30 27
ALL 26 8
CML 26 43
CLL — 3
MDS 15 15
Other 1 7
% Prior busulfan use 2 5 0.11
Prescribed total body radiation dose
(cGy), mean
1200 1360 o0.001
Prescribed lung radiation dose
(cGy), mean (range)
714
(600–900)
1360
(1360–1360)
o0.001
Abbreviation: MDS¼myelodysplastic syndrome.
P-values for continuous variables are based on a two-sided Wilcoxon rank-
sum test. P-values for frequencies are based on two-sided Fisher’s exact tests.
Table 2 Total change in PFT values
1-year follow-up 2-year follow-up
Lung shielding No lung shielding P-values Lung shielding No lung shielding P-values
2.5 5.5 0.004 2.0 2.0 0.41
FEV1 (3.0 to 8.3) (16.8 to 2.8) (6.0 to 4.0) (12.8 to 1.8)
n¼ 40 n¼ 38 n¼ 33 n¼ 30
15.0 17.5 0.61 18.0 15.0 0.78
DLCO (28.5 to 5.0) (29.0 to 4.8) (32.3 to 2.0) (25.8 to 7.8)
n¼ 39 n¼ 36 n¼ 32 n¼ 30
2.0 3.0 0.009 2.0 2.0 0.34
VC (3.3 to 6.5) (14.0 to 1.0) (6.0 to 4.0) (12.8 to 17.5)
n¼ 40 n¼ 38 n¼ 33 n¼ 30
Abbreviations: DLCO¼ diffusion capacity for carbon monoxide; FEV1¼ forced expiratory volume in the ﬁrst second; PFT¼ pulmonary function testing;
VC¼ vital capacity.
The median change in PFT measurements from pretransplant to 1 year and 2 years after transplant is compared between lung shielding groups for all
patients. Values represent the median change in PFT values, measured as % predicted, with range from 1st to 3rd quartile. The FEV1 and VC are
signiﬁcantly different between those patients with lung shielding and those with no lung shielding at the 1-year time point. There are no signiﬁcant differences
between the groups at the 2-year time point. P-values are based on a two-sided Wilcoxon rank-sum test.
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pulmonary function, especially for patients with poor
pretransplant PFT values. Although these ﬁndings are
statistically signiﬁcant, they are not likely to be clinically
signiﬁcant and do not fully explain our previous ﬁnding
that lung dose reduction improves survival of transplant
patients with initial FEV1 and DLCO less than 100% of
predicted.35
Lung dose reduction was attempted by Molls et al.17 who
found that a dose of 9.3Gy at high dose rate can result in
interstitial pneumonitis in up to 50% of treated patients.
Labar et al.28 randomized 64 patients with leukemia to
receive TBI with or without lung dose reduction The
probability of interstitial pneumonitis decreased from 15 to
5% with lung dose reduction, and there was no impact on
the rate of relapse. Although the results were not
statistically signiﬁcant, they do show a trend toward
protection against interstitial pneumonitis with lung
shielding. Weshler et al.42 randomized 44 patients to receive
TBI to a total dose of 12Gy with or without lung dose
reduction to 6Gy. The rate of interstitial pneumonitis in
the unshielded group was 26% versus none in the shielded
group.42
Similarly, in a prior analysis we found reduced pulmon-
ary mortality (10 vs 3%, P¼ 0.08) with lung dose reduced
TBI.35 The current analysis shows that TBI has a minimal
impact on long-term, post transplant pulmonary function,
which is not likely to be clinically signiﬁcant. There is a
small, but statistically signiﬁcant beneﬁt to lung dose
reduction at 1 year, which is seen in patients with poor
(p100% predicted) preirradiation PFT values but not
good (4100% predicted) preirradiation PFT values.
This ﬁnding is in agreement with prior studies that have
Table 3 Total change in PFT values at 1 year by preirradiation function
Good preirradiation PFTs Poor preirradiation PFTs
Lung shielding No lung shielding P-values Lung shielding No lung shielding P-values
0 3.5 0.07 7.0 8.0 0.03
FEV1 (4.0 to 5.0) (17.5 to 1.3) (2.5 to 13.0) (15.8 to 3.8)
n¼ 21 n¼ 20 n¼ 19 N¼ 18
28.5 28.0 0.60 6.0 10.0 0.30
DLCO (36.8 to 18.3) (38.0 to 26.0) (15.0 to 6.0) (22.0 to 2.0)
n¼ 18 n¼ 13 n¼ 21 n¼ 23
2.0 3.0 0.42 3.5 3.0 0.007
VC (9.3 to 1.25) (16.0 to 1.0) (0 to 8.8) (14.0 to 1.0)
n¼ 14 n¼ 13 n¼ 26 n¼ 25
Abbreviations: DLCO¼ diffusion capacity for carbon monoxide; FEV1¼ forced expiratory volume in the ﬁrst second; PFT¼ pulmonary function testing;
VC¼ vital capacity.
The median change in PFT measurements from pretransplant to 1 year after transplant is compared between lung shielding groups after stratiﬁcation
by good and poor preirradiation PFT measurements. Values represent the median change in PFT values, measured as % predicted, with range from 1st to
3rd quartile. There was a statistically signiﬁcant difference in the change in lung function between those patients with lung shielding and those with no lung
shielding for patients with poor (p100% predicted) preirradiation PFTs. There were no signiﬁcant differences in lung function for patients with good
(4100% predicted) preirradiation PFTs. P-values are based on a two-sided Wilcoxon rank-sum test.
Table 4 Rate of change of PFT values during 1-year follow-up
All patients Good pre-irradiation PFTs Poor pre-irradiation PFTs
Lung shielding No lung shielding P-values Lung shielding No lung shielding P-values Lung shielding No lung shielding P-values
0.40 0.11 0.33 0.78 0.14 0.90 1.2 0.11 0.08
FEV1 (2.8 to 2.9) (4.6 to 1.7) (5.6 to 2.1) (4.8 to 2.1) (1.0 to 5.4) (4.3 to 0.9)
n¼ 46 n¼ 49 n¼ 24 n¼ 22 n¼ 22 n¼ 22
3.7 3.3 0.64 6.5 6.5 0.78 1.0 2.4 0.40
DLCO (7.9 to 0.8) (9.2 to 0.2) (16.8 to 4.6) (10.5 to 2.9) (4.9 to 2.0) (6.9 to 0.51)
n¼ 46 n¼ 44 n¼ 18 n¼ 17 n¼ 27 n¼ 26
0.98 0.05 0.41 1.4 0.08 0.86 1.8 0.02 0.19
VC (2.9 to 2.7) (2.4 to 2.2) (7.30 to 1.4) (6.1 to 1.6) (1.1 to 4.7) (1.7 to 2.2)
n¼ 46 n¼ 44 n¼ 16 n¼ 15 n¼ 30 n¼ 29
Abbreviations: DLCO¼ diffusion capacity for carbon monoxide; FEV1¼ forced expiratory volume in the ﬁrst second; PFT¼ pulmonary function testing;
VC¼ vital capacity.
The median rate of change per year (range from 1st to 3rd quartile) in PFT parameter measurements (% predicted value) as determined by least-squares
regression from pretransplant to 1 year after transplant, is compared between lung shielding groups for all patients, and stratiﬁed by good (4100%
predicted) and poor (p100% predicted) preirradiation PFT values. There was no statistically signiﬁcant difference in the rate of change in lung function
between those patients with lung shielding and those with no lung shielding. P-values are based on a two-sided Wilcoxon rank-sum test.
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reported that TBI does not result in signiﬁcant deteriora-
tion of long-term lung function despite causing severe
acute morbidity in the form of interstitial pneumonitis, and
even death.37,43,44
In a study of patients with osteogenic sarcoma who
received adjuvant therapy consisting of whole-lung irradia-
tion (with the heart shielded), Ellis et al.43 found decreased
in FEV1, VC and DLCO during the ﬁrst 6–12 months after
irradiation. These values returned to baseline, however,
during the second year following irradiation and remained
at baseline throughout the remainder of the follow-up
period.43 Gore et al.44 also found that while pulmonary
function declined initially, it recovered to baseline levels at
approximately 1 year and remained stable 2 years post-
irradiation Radiation dose to the lungs was identiﬁed as
one factor that delayed or impaired recovery of pulmonary
function. Carlson et al.,37 in a study of over 1200 patients,
also found that the major risk factor for pulmonary
complications was lung dose but that ventilatory dysfunc-
tion following TBI was usually mild and had no clinical
signiﬁcance. In our recent study of long-term PFT after
allogeneic stem cell transplantation, we found no difference
in PFT between reduced-intensity (non-radiated) patients
and those getting TBI after median follow-up of 7.5 years
(range 5–13 years).45
Conclusion
TBI plays an important role in conditioning regimens for
bone marrow transplant and PBSCT. Decreasing the
radiation dose to the lung can decrease pulmonary-related
mortality. TBI, with or without lung shielding, has minimal
effect on PFTs at 1 and 2 years post-irradiation. The small
improvement in post transplant PFTs with lung dose
reduction regimens is of little clinical signiﬁcance. There-
fore, lung dose reduction should be employed primarily as
a means to decrease mortality in high-risk patients and not
to prevent long-term deterioration in pulmonary function.
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